Researchers are investigating CBL-514, an injectable compound, as a potential obesity intervention on the basis that it may prompt adipocytes — the cells responsible for storing fat in the body — to undergo apoptosis, a natural cellular process in which cells break down and eliminate themselves. Findings on CBL-514 were presented at the European Association for the Study of Diabetes gathering held in Milan.
Preliminary findings from a phase of human trials, shared at that gathering, showed that the investigational injection targeting adipose tissue in the abdominal region prompted those cells to break down, with participants displaying a measurable reduction in visceral fat deposits.
Caliway Biopharmaceuticals, a company headquartered in New Taipei City, Taiwan, produced the compound under investigation, with data drawn from a pair of phase 2 trials — designated CBL-0204 and CBL-0205 — in which MRI scanning served as the tool for quantifying visceral fat accumulated within the abdominal cavity. Abdominal injections were administered to study participants every three weeks across a period of up to 12 weeks, with enrolment limited to those whose body mass index — commonly expressed as BMI — fell between 22 and 30 kg/m².
Within the visceral fat subgroup, dosing reached a ceiling of 600 mg, with 23 participants assigned to CBL-514 and 17 allocated to the placebo arm. Participant group ages fell within a span running from a low of 36.4 years up to a high of 42.4 years.
Visceral fat accumulates around internal organs — the liver and intestines being examples — rather than pooling just under the skin, and this deeper fat variety goes largely undetected. Research has established an association between this variety of fat and conditions including insulin resistance, type 2 diabetes, and broader disorders of cardiometabolic health.
By the later assessment point, those receiving CBL-514 had reduced their visceral fat volume to a level 10.45% beneath their starting measurement, whereas participants on placebo saw that same measure climb 11.76% above their own baseline. By the time a month had passed since the last dose, those who received the treatment showed an average drop of 12.01% in visceral fat volume, while participants on the placebo saw that same measure rise by 5.68% on average.
Quantifiable effects on the outer layer of belly fat were among the findings the research team put forward. By the eight-week assessment point, roughly seven in ten participants receiving CBL-514 had shed at least 150 mL of subcutaneous fat volume, a threshold not reached by anyone in the placebo arm.
Data gathered across multiple trials points to the injection altering both subcutaneous and visceral fat deposits. Shrinking that internal fat layer carries consequences beyond a reduction in waist size, given that the tissue operates as a hormonally active depot with documented links to how the body regulates glucose and processes energy.
W. Timothy Garvey at the University of Alabama at Birmingham noted that the treatment's value may extend beyond aesthetics, adding that patients are anticipated to welcome physical changes such as a reduction in abdominal fullness linked to subcutaneous fat loss. Reductions in body weight and visceral fat, along with improvements in blood pressure and cholesterol levels, are what matter most for health outcomes, he noted.
Where treatments such as GLP-1 receptor agonists work chiefly by curbing hunger or limiting how much fat tissue can store, this pathway operates on a distinct biological principle. Post-treatment weight return has complicated what once appeared to be a clear path forward for obesity medications, leaving the field with a biological problem that investigators are actively working to resolve.
The potential to limit weight returning after a patient discontinues GLP-1 medications is among the benefits the treatment's developers point to, though evidence for this effect remains confined to animal studies. Garvey noted that CBL-514 holds potential for limiting the weight that patients regain once they discontinue GLP-1 receptor agonist therapies — a category that includes Ozempic, Wegovy, Mounjaro, and Zepbound — though the supporting evidence for that possibility remains confined to animal research at this stage.
Across those trials, pairing CBL-514 with tirzepatide drove down body weight beyond what tirzepatide delivered on its own, and animals that had received the combination held onto less of that lost weight once tirzepatide was withdrawn. Researchers have yet to replicate in human subjects what animal studies have indicated about weight returning after loss, leaving the body of data at a preliminary stage.
Adverse reactions recorded across those initial trials were largely confined to brief, localised responses at the point of injection — notably discomfort, localised swelling, and skin redness — with the therapy itself proving broadly acceptable to participants. No harmful outcomes meeting the threshold for medical classification turned up in the study data.
Findings shared at the Milan conference point toward a potential next phase in obesity care — an injectable therapy aimed not merely at reducing fat tissue, but at clearing away the underlying fat cells entirely.
